Heartland Cancer Research CCOP (Heartland) offers participation in NCI-sponsored cooperative group protocols in cancer treatment, control, and prevention research to the metropolitan and rural communities of Eastern and Central Missouri, including medically under-served rural communities. This research ultimately facilitates the introduction of newly developed cancer prevention strategies, early detection techniques, cancer treatment and symptom management interventions not only to these same populations, but also nationally. Heartland's main component, Missouri Baptist Medical Center (MBMC), has a long history of high-quality clinical oncology research. The elements of that research include: 1) 7 medical oncologists and associated professional staff with clinical trial experience, 2) diligent protection of human subjects according to federal regulations, 3) established, successful participant eligibility screening procedures, and 4) refined protocol compliance and data management procedures. Affiliates in Jefferson City (Capitol Region Medical Center) and Cape Girardeau, Missouri (Southeast Health) provide clinical trial participation opportunities to over 3 counties in rural Missouri. Heartland will maintain a wide menu of clinical trials in order that physicians will have a protocol available for the majority of their cancer patients. CRA and research nursing staff will facilitate the process of entering patients on study, assuring protocol compliance, and submitting data, specimens, and tissue in a timely basis. In addition to their accrual and data management efforts. Heartland members make contributions to the group life of the Alliance and NSABP through committee participation and ad hoc auditing. Heartland continues to expand the existing research program to a wide geographic area to Improve the cancer-related health of the suburban and rural communities served by the CCOP.
Heartland was developed to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer treatment, and prevention and control interventions to the populace of St. Louis County and contiguous, medically under-served rural areas in Missouri. Through Heartland's network of clinics, clinical research access is provided to more than thirty counties in eastern, central, and southern Missouri that would not otherwise be available.
|Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21|
|Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89|
|Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43|
|Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17|
|Wolf, Sherry L; Qin, Rui; Menon, Smitha P et al. (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182-7|
|Miller, Antonius A; Pang, Herbert; Hodgson, Lydia et al. (2010) A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 5:380-4|
|Yao, Song; Barlow, William E; Albain, Kathy S et al. (2010) Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16:6169-76|
|Lyss, Alan P; Lilenbaum, Rogerio C (2009) Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program. Clin Lung Cancer 10:410-3|
|Ambrosone, Christine B; Barlow, William E; Reynolds, Wanda et al. (2009) Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol 27:4973-9|
|Philips, G K; Halabi, S; Sanford, B L et al. (2009) A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 20:1074-9|
Showing the most recent 10 out of 14 publications